| Biomarker ID | 590 |
| PMID | 21305254 |
| Year | 2011 |
| Biomarker | Albumin (ALB); Annexin A4 (ANXA4); Apolipoprotein A-I (APOA1); ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B); Fibrinogen γ chain (FGG); |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Stage T3 (Fold Change) : Albumin (ALB) [2.684]; Annexin A4 (ANXA4) [1.000]; Apolipoprotein A-I (APOA1) [2.691]; ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B) [1.000]; Fibrinogen γ chain (FGG) [1.000]; |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(ALB):- HDL-mediated lipid transport,Transport of vitamins, nucleosides, and related molecules,Transport of organic anions,Folate metabolism,Vitamin B12 metabolism Pathways Include(APOA1):-Folate metabolism,PPAR signaling pathway,Selenium pathway, Mechanism of gene regulation by peroxisome proliferators via PPAR alpha,Vitamin B12 metabolism |
| Experiment | Stage T2 Vs Stage T3 |
| Type of Biomarker | Prognostic |
| Cohort | Samples from 16 patients diagnosed with BPH along woth 8 patients with prostate cancer were chosen. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | MALDI-TOF-MS |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ALB, ANXA4, APOA1, ATP5B, FGG |